MapLight Therapeutics (MPLT) Assets Average (2025 - 2026)

MapLight Therapeutics (MPLT) posted Assets Average of $368.4 million for Q4 2025, up 86.92% sequentially from $197.1 million in Q3 2025.

MapLight Therapeutics (MPLT) Assets Average (2025 - 2026) Analysis & Trends

MapLight Therapeutics has reported Assets Average for 1 years, with the latest figure at $368.4 million in Q4 2025.

Quarterly Assets Average changed N/A year-over-year to $368.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $368.4 million (changed N/A YoY) and the FY2025 annual result came in at $308.2 million, changed N/A from the prior year.
Assets Average climbed to $368.4 million in Q4 2025 per MPLT's latest filing, from $197.1 million in the prior quarter.
Over five years, Assets Average peaked at $368.4 million in Q4 2025 and troughed at $197.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	26.95 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	41.30 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	3.29 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	8.86 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	16.08 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.82 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	5.34 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	2.09 Bn
10	MapLight Therapeutics	533.88 Mn	533.88 Mn	-	423.93 Mn

Download Data